Elicio Therapeutics ELTX 深 沪
已收盘 08-28 16:00:00 美东时间
2.84
-0.160
-5.33%
华盛通- 最 高3.00
- 今 开3.00
- 成交量 42.16万股
- 最 低 2.84
- 昨 收 3.00
- 总市值 7464.05万
- 52周最高 16.00
- 市盈率 静 --
- 换手率 1.60%
- 52周最低 2.66
- 委 比 79.38%
- 总股本 2628.19万
- 历史最高 263.00
- 量 比 1.87
- 振 幅 5.33%
- 历史最低 2.66
- 每 手 1
- 风险率 3.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Elicio Therapeutics, a clinical-stage biotech company developing immunotherapies for KRAS-driven cancers, announced that its management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, in Boston. The company focuses on off-the-shelf immunotherapy candidates targeting common cancer mutations, including KRAS, BRAF, and p53, aiming for rapid manufacturing and patient access. For more...
08-24 12:00
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $23 price target.
08-18 19:27
Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate
Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 34.85 percent increase over losses of $(0.66) per share from the same period last year.
08-14 04:18
11 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma (NASDAQ:LIMN) shares rose 26.04% to $0.14. The market value of their outstanding shares is at $5.8 milli...
07-03 01:05
Ladenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12
Ladenburg Thalmann analyst Kevin DeGeeter assumes Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $12.
06-19 03:03
美股夜盘 | Linkers Industries Limited Class A涨40.63%，Rumble涨17.42%
Sleep Number Corporation涨-31.44%；Elicio Therapeutics, Inc涨-19.11%；君长数码涨-13.15%
06-18 08:05
Jones Trading Downgrades Elicio Therapeutics to Hold
Jones Trading analyst Boris Peaker downgrades Elicio Therapeutics (NASDAQ:ELTX) from Buy to Hold.
06-17 00:30
美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
Elicio Therapeutics Pancreatic Cancer Study Disappoints
Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is trading lower on Monday after disappointing results from its Phase 2 AMPLIFY-7P study of ELI-002 7P in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) following standard locoregional treatment. Elicio Therapeutics Misses Primar...
06-16 00:29
